Skip to main content
. Author manuscript; available in PMC: 2016 Aug 16.
Published in final edited form as: Lancet Neurol. 2013 Jan 31;12(3):233–243. doi: 10.1016/S1474-4422(13)70014-0

Table 3.

AUC of the Aβ plasma change from the trough level in the 4-week dosing interval (Intent-to-treat population; n=55).

IVIG (n=21) Placebo (n=7) Placebo vs. 0.2 IVIG Placebo vs. 0.5 IVIG Placebo vs. 0.8 IVIG
0.2 (n=6) 0.5 (n=8) 0.8 (n=7)
Aβ1–40 −18.00
[−1347.0; 1068.5]
(n=6)		 −364.25
[−5834.5; 1953.5]
(n=8)		 −351.75
[−1084.0; 936.5]
(n=7)		 −116.25
[−1379.0; 5266.0]
(n=6)		 −32.50
[−1358.0; 4197.5]
p=0.8102		 195.25
[−1005.5; 5302.0]
p=0.7469		 235.50
[−984.5; 4329.5]
p=0.5752
Aβ1–42 −41.75
[−244.40; 336.55]
(n=6)		 −119.25
[−1220.60; 375.00]
(n=8)		 −107.50
[−173.50; 231.00]
(n=6)		 −20.50
[−183.70; 489.00]
(n=6)		 30.25
[−234.55; 346.40]
p=0.5752		 114.75
[−64.50; 622.00]
p=0.2200		 87.00
[−95.70; 275.50]
p=0.2298
nAbs-Aβ 932.50
[−2991.5; 3577.0]
(n=6)		 5770.00
[2892.5; 14426.0]
(n=8)		 8658.75
[5532.5; 11517.5]
(n=6)		 636.00
[−1207.5; 1075.5]
(n=6)		 −915.50
[−2844.5; 1784.0]
p=0.5752		 −5339.50
[−7203.5; −3814.5]
p=0.0024 		−8398.25
[−10785.0; −5343.5]
p=0.0051

Data are median [minimum, maximum] (patients analysed) for treatment groups; differences are assessed by Hodges-Lehmann estimates of the difference in two medians and the corresponding non-parametric 95% confidence interval (exact) as well as by Wilcoxon Rank Sum test (normal approximation, two-sided, α=0.05).